FivePrime waves bye to CEO; Allos moves into PhIII with lymphoma drug;

@FierceBiotech: Stanford investigators use "online dating" to match old drugs with new medical uses. Story | Follow @FierceBiotech

@JohnCFierce: Funny Icahn threat in conceding Forest BOD vote. Imclone, Biogen, Genzyme all took time. (I'll be baa-a-a-ack.) More | Follow @JohnCFierce

@RyanMFierce: Hmm. Ireland-based academic says that private biotech spin-offs do better than those from universities Piece | Follow @RyanMFierce

@MaureenFierce: The other dark side of Merck's 13,000 layoffs: Pharma's moving to greener pastures. Story | Follow @MaureenFierce

> FivePrime Therapeutics' CEO, Julia Gregory, has resigned from her post and company founder Lewis Williams is now listed as the firm's chief executive. In Vivo report

> The Irish Times reports a study that found that private-sector biotech spin-offs "outperform" their counterparts from universities. Article

> Allos Therpeutics ($ALTH) reports that it has begun a Phase III trial of Folotyn for patients with certain cases of peripheral T-cell lymphoma. Item

> Apricus Biosciences says ($APRI) says that the FDA has cleared its subsidiary's over-the-counter anti-fungal drug, Tolnaftate-D. Apricus release

> With plans to fund its clinical-stage compounds, Furiex Pharmaceuticals ($FURX) has garnered a loan deal from MidCap Financial and Silicon Valley Bank that enables the firm to get up to $15 million. Announcement

Pharma News

@FiercePharma: Ranbaxy could waive Lipitor rights, let a rival generic to market... for a fee. If it can't get straight with FDA first. Article | Follow @FiercePharma

> Paladin CEO in hospital after cycling accident. Article

> Japan asks Boehringer to warn docs on Pradaxa. Report

> Drugmakers take a hit on Greek bonds. News

> Vertex's Incivek could top $1B this year, analyst says. Item

And Finally... One in 5 people seeking bankruptcy protection blames medical bills. Report

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.